A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease

[1] Libby P(2005)Pathophysiology of coronary artery disease Circulation 111 3481-3488

[2] Theroux P(2020)ESC guidelines for the diagnosis and management of chronic coronary syndromes Eur Heart J 41 407-477

[3] Knuuti J(2021)2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Rev Esp Cardiol (Engl Ed) 74 544-1600

[4] Wijns W(1992)Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty J Am Coll Cardiol 19 1597-3507

[5] Saraste A(2018)Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Eur Heart J 39 3499-762

[6] Capodanno D(2019)Low-dose methotrexate for the prevention of atherosclerotic events N Engl J Med 380 752-68

[7] Barbato E(2017)Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians Ann Intern Med 166 58-651

[8] Funck-Brentano C(2016)EULAR recommendations for the management of familial Mediterranean fever Ann Rheum Dis 75 644-1506

[9] Collet JP(2015)Evaluation and treatment of pericarditis: a systematic review JAMA 314 1498-390

[10] Thiele H(1982)Antitubulins—a new therapeutic approach for atherosclerosis? Atherocslerosis 44 385-115

[1] Libby P(2005)Pathophysiology of coronary artery disease Circulation 111 3481-3488

[2] Theroux P(2020)ESC guidelines for the diagnosis and management of chronic coronary syndromes Eur Heart J 41 407-477

[3] Knuuti J(2021)2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Rev Esp Cardiol (Engl Ed) 74 544-1600

[4] Wijns W(1992)Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty J Am Coll Cardiol 19 1597-3507

[5] Saraste A(2018)Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Eur Heart J 39 3499-762

[6] Capodanno D(2019)Low-dose methotrexate for the prevention of atherosclerotic events N Engl J Med 380 752-68

[7] Barbato E(2017)Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians Ann Intern Med 166 58-651

[8] Funck-Brentano C(2016)EULAR recommendations for the management of familial Mediterranean fever Ann Rheum Dis 75 644-1506

[9] Collet JP(2015)Evaluation and treatment of pericarditis: a systematic review JAMA 314 1498-390

[10] Thiele H(1982)Antitubulins—a new therapeutic approach for atherosclerosis? Atherocslerosis 44 385-115